Coronavirus (COVID-19 ou SARS-COV-2): clinical trials assessment

Authors

DOI:

https://doi.org/10.9771/cp.v13i2.36175

Keywords:

Pandemics, Therapies, Technology Assessment, Technology Readiness Levels, TRL.

Abstract

Clinical tests (TRL5 to TRL9) of the new corona virus have been mapped in order to obtain the current state of the art. The international base of the World Health Organization was mapped and complemented with national bases. After screening, 661 documents remained and were analyzed. There are studies in 25 countries, although they are concentrated in China. Companies finance less than 6% of studies. The vast majority of studies are in Phase Zero (preclinical), only 2% are already in progress and none has results yet. Their primary goals are therapeutics; however, a large majority are dedicated to Chinese medicine and only 245 are focusing on antiviral, immunotherapy and vaccine transnational technologies. There is a wide range of active compounds, mainly referring to hydroxychloroquine/chloroquine (31) and stem cells (22). The age groups of the patients focus especially on adolescents and adults and leave long-lived patients uncovered. 

Downloads

Download data is not yet available.

Author Biographies

Cristina M. Quintella, Federal University of Bahia

  • Endereço para acessar este CV: http://lattes.cnpq.br/7897779819494573
  • ID Lattes: 7897779819494573

Heitor da Mata Quintella, Federal University of Minas Gerais

Address to access this CV: http://lattes.cnpq.br/6843746810740529 Graduated in Architecture and Urbanism from the Federal University of Bahia (2007-2011). Studying a degree in Medicine (2016 - Current) at the Federal University of Minas Gerais, Brazil.

Giovanni Batista Palma, Federal University of Minas Gerais

http://lattes.cnpq.br/2196060104720570 Born in Belo Horizonte, MG. Graduated in high school integrated to the Clinical Analysis course (2011-2014), with a practical internship of 720 hours. Currently studying Medicine at the Faculty of Medicine of UFMG (2016) and English course at UPTIME (2018). He is currently participating in a scientific initiation project under the guidance of Professor Paulo Caramelli at the Ambulatory of Cognitive Neurology and Behavior at UFMG (ANCC-UFMG) and participant in the extension project of Horto Medicinal Frei Veloso at UFMG (2018).

Gustavo Henrique Ramos Silva, Federal University of Minas Gerais

Endereço para acessar este CV: http://lattes.cnpq.br/3352093665267223

References

ALBUQUERQUE, E. M.; SOUZA, S. G. A.; BAESSA, A. R. Pesquisa e inovação em saúde: uma discussão a partir da literatura sobre economia da tecnologia. Ciênc. Saúde Colet., [S.l.], v. 9, p. 277-294, 2000.

BERKLEY, S. COVID-19 needs a Manhattan Project. Science, [S.l.], v. 367, Issue 6485, p. 1.407, 2020. DOI: 10.1126/science.abb8654.

GUAN, Wei-Jie et al. Clinical characteristics of coronavírus disease 2019 in China. New England Journal of Medicine, [S.l.], 2020.

HOFFMANN, Markus et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, [Elsevier BV], p. 1-10, mar. 2020. Disponível em: http://dx.doi.org/10.1016/j.cell.2020.02.052. Acesso em: 25 mar. 2020.

IBM. Digital Nordic. [2020]. Disponível em: https://www.ibm.com/blogs/nordic-msp/ibm-supercomputer-summit-attacks-coronavírus/. Acesso em: 1º mar. 2020.

ICTRP – INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM. [2020]. Disponível em: https://www.who.int/ictrp/en/. Acesso em: 27 mar. 2020.

MCINTOSH, K. Coronavírus disease 2019 (COVID-19). UpToDate. Hirsch MS, Bloom A (ed.). [2020]. Disponível em: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention. Acesso em: 30 Mar. 2020.

NIHCT – U. S. National Library of Medicine. Clinical Trials. [2020]. Disponível em: https://clinicaltrials.gov/. Acesso em: 15 mar. 2020.

QUINTELLA, C. M. et al. Maturidade Tecnológica: Níveis de Prontidão TRL. In: MOURA RIBEIRO, Núbia. (org.). PROFNIT, Prospecção Tecnológica. 1. ed. Salvador, BA: Editora do IFBA, 2019. v. 2, p. 18-59. Disponível em: http://www.profnit.org.br/pt/livros-profnit/.Acesso em: 2 abril. 2020.

QUINTELLA, C. M. et al. Vacinas para Coronavírus (COVID-19; SARS-COV-2): mapeamento preliminar de artigos, patentes, testes clínicos e mercado. Cadernos de Prospecção, Salvador, v. 13, p. 3-12, 2020. DOI: 10.9771/cp.v13i1.35871.

ROTHE, C.; SCHUNK, M.; SOTHMANN, P. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. [S.l.], 2020. Disponível em: https://doi.org/10.1056/NEJMc2001468. Acesso em: 25. mar. 2020.

WANG, H. J. et al. Review and Prospect of Pathological Features of Coronavírus Disease. Fa Yi Xue Za Zhi, [S.l.], v. 36, n. 1, p. 16-20, 2020a.

WANG, C. et al. A novel coronavírus outbreak of global health concern. Lancet, [S.l.], 2020b. Disponível em: https://doi.org/10.1016/S0140-6736(20)30185-9. Acesso em: 25. mar. 2020.

WHO – ORGANIZAÇÃO MUNDIAL DE SAÚDE. International Standards for Clinical Trial Registries, 10 de janeiro de 2018. Disponível em: https://www.who.int/publications-detail/international-standards-for-clinical-trial-registers. Acesso em: 2 abr. 2020.

WHO – WORLD HEALTH ORGANIZATION. Novel Coronavírus (2019-nCoV) Situation Report-1. [2020a].Disponível em: https://www.who.int/docs/default-source/coronavíruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4. Accesso em: 25 mar. 2020.

WHO – WORLD HEALTH ORGANIZATION. Novel Coronavírus (2019-nCoV) Situation Report-70. [2020b]. Disponível em: https://www.who.int/docs/default-source/coronavíruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_2. Accesso em: 25 mar. 2020.

WHO – WORLD HEALTH ORGANIZATION. Novel Coronavírus (2019-nCoV) technical guidance. [2020c]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavírus-2019/technical-guidance. Accesso em: 25 mar. 2020.

WHO – WORLD HEALTH ORGANIZATION. Situation reports. 2019. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavírus-2019/situation-reports/ Accesso em: 22 feb. 2020.

XIAO-WEI, Xu et al. Clinical findings in a group of patients infected with the 2019 novel coronavírus (SARS-Cov-2) outside of Wuhan, China: retrospective case series BMJ, [S.l.], v. 368, m606, 2020.

XINHUANET. China’s CDC detects a large number of new coronavíruses in the South China seafood market in Wuhan. [2020]. Disponível em: https://www.xinhuanet.com/2020-01/27/c_1125504355.htm. Accesso em: 2 fev. 2020.

YI, Y. et al. COVID-19: what has been learned and to be learned about the novel coronavírus disease. International Journal of Biological Sciences, [S.l.], v. 16, n. 10, p. 1.753, 2020.

Downloads

Published

2020-04-16

How to Cite

Quintella, C. M., Quintella, H. da M., Palma, G. B., Silva, S. C. R. da, & Silva, G. H. R. (2020). Coronavirus (COVID-19 ou SARS-COV-2): clinical trials assessment. Cadernos De Prospecção, 13(2), 397. https://doi.org/10.9771/cp.v13i2.36175

Issue

Vol. 13 No. 2 (2020): Edição Especial - Coronavírus (SARS-COV-2) e COVID-19

Section

Coronavirus (SARS-COV-2) e COVID-19

License

Copyright (c) 2020 Cadernos de Prospecção

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos. Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.